ライフサイエンスコーパス: viraemia

1 a detectable viral load (local prevalence of viraemia).

2 y has a role in reduction of cytomegalovirus viraemia.

3 t HCMV serostatus was also a risk factor for viraemia.

4 dren, resulting in antigenaemia and possible viraemia.

5 wed by a slower second-phase decay of plasma viraemia.

6 ars), 32/106 (30.2%) patients experienced BK viraemia.

7 harder-to-reach populations with persistent viraemia.

8 atients in either group had hepatitis D or E viraemia.

9 iretroviral therapy (ART) have high rates of viraemia.

10 C(min)) were determined for individuals with viraemia.

11 caprevir-pibrentasvir only if they developed viraemia.

12 s adverse event (SAE) or experienced rebound viraemia.

13 responses that overlapped with the period of viraemia.

14 le, or the public health impact of low-level viraemia.

15 ere also strong risk factors for post-partum viraemia.

16 T cells and the rapid reappearance of plasma viraemia.

17 h higher ranges and persistence of low-level viraemia.

18 ion of HIV-positive partners with detectable viraemia.

19 ties with an at least 5% local prevalence of viraemia.

20 IV infection have a high risk of post-partum viraemia.

21 th-care providers 6 weeks after clearance of viraemia.

22 o ART strongly predict time to the return of viraemia.

23 Two patients receiving ART had transient HIV viraemia.

24 ection of rhesus monkeys and before systemic viraemia.

25 g the 'eclipse' phase, and before detectable viraemia.

26 seroconversion and extended the duration of viraemia.

27 IV dissemination and strongly reduced plasma viraemia.

28 lated significantly with reduced acute phase viraemia.

29 infected were half as likely to develop new viraemia (12% [12/98]), even after accounting for risk b

30 rebound viraemia (55 [53%]), and persistent viraemia (18 [17%]).

31 years, 18.8-22.2), or persistent post-partum viraemia (19.0 years, 17.7-20.5).

32 ears, IQR 19.4-25.9) than those with rebound viraemia (20.4 years, 18.8-22.2), or persistent post-par

33 suppression (<=50 copies per mL), low-level viraemia (51-999 copies per mL), virological non-suppres

34 ng sustained suppression (31 [30%]), rebound viraemia (55 [53%]), and persistent viraemia (18 [17%]).

35 -week 24 was spent with persistent low-level viraemia (80-5,000 copies/ml) and 10% with VL rebound >/

36 0001), and summed PET signal correlated with viraemia across a 4 log range (r2=0.98, p<0.0001).

37 participants without cytomegalovirus plasma viraemia (adjusted odds ratio 2.31 [95% CI 1.12-4.75] at

38 We assumed 50% of children who had viraemia after abacavir-lamivudine exposure had NRTI res

39 ions and the often asymptomatic herpes-virus viraemia after DRESS.

40 -1 gag/pol/nef vaccine did not reduce plasma viraemia after infection, and HIV-1 incidence was higher

41 ressed for more than 20 weeks showed rebound viraemia after one of the antibodies reached serum conce

42 In those who developed viraemia after transplantation, glycoprotein-B antibody

43 ction in mice and non-human primates against viraemia after Zika virus challenge.

44 Here we show that, despite rebound in viraemia, all subjects were able to achieve at least a t

45 inhibitors (NRTIs) for children with HIV and viraemia alongside dolutegravir-based ART is beneficial

46 tential HIV transmission risk and detectable viraemia among serodiscordant couples warrant intensifie

47 HCV antibody positive, 213 (54%) of whom had viraemia and 104 (26%) of whom knew their antibody statu

48 High fever, viraemia and abnormalities in blood count and blood chem

49 0% survival, even when initiated when fever, viraemia and disease signs were evident.

50 sed the prevalence of cytomegalovirus plasma viraemia and EBV plasma viraemia, and CNS co-infections,

51 severe and fatal infection, characterized by viraemia and extrapulmonary spread.

52 combination antiretroviral therapy (ART) on viraemia and immune responses, sexual risk behaviour, an

53 Pre-conception viraemia and immune suppression were also strong risk fa

54 occurrence and recurrence of cytomegalovirus viraemia and improved the time-to-event for viraemia epi

55 t the individual level, including increasing viraemia and mortality, and increases the risk for ongoi

56 multimerized and biparatopic Bicycles reduce viraemia and prevent host inflammation.

57 relations between immunosuppression and HIV viraemia and risk for non-Hodgkin lymphoma, a common can

58 d that identify protection as the absence of viraemia and the absence of an anamnestic antibody respo

59 rol coincides with a final escalation of the viraemia and the terminal failure of the immune system.

60 pies per mL, had increased odds of low-level viraemia and virological non-suppression at next viral l

61 A more than 150 copies per mL (prevalence of viraemia); and the proportion of participants with HIV w

62 tomegalovirus plasma viraemia and EBV plasma viraemia, and CNS co-infections, associations between cy

63 Younger age at conception, pre-conception viraemia, and pre-conception immune suppression could id

64 Immunogenicity, viraemia, and shedding post-vaccination were evaluated a

65 C117 is safe and effective in reducing HIV-1 viraemia, and that immunotherapy should be explored as a

66 We defined viraemia as 400 copies per mL or more.

67 oved HCV drug, suppressed more than 3 log of viraemia but is associated with the emergence of resista

68 d defective particles may interfere with the viraemia, but the generated defective virus particles ar

69 lonal antibodies have been shown to suppress viraemia, but the therapeutic potential of these monoclo

70 mild in adults, with quickly resolved blood viraemia, but ZIKV might persist for months in saliva, u

71 onic long-term HIV-1 patients who had stable viraemia by RT-PCR (non-progressors).

72 For participants with undetectable viraemia by TaqMan, there was poor concordance without c

73 ast 200 copies per mL of blood and low-level viraemia can lead to virological failure; the threshold

74 oviral-therapy-naive study participants with viraemia carrying sensitive virus at the baseline.

75 proximately tenfold lower vaccine-associated viraemia compared to the first-generation vaccine and bo

76 al immunity by vaccination might achieve CMV viraemia control without the need for antiviral agents.

77 revalence of pretreatment HIV drug-resistant viraemia decreased due to increasing ART uptake and vira

78 eles of the B58 supertype associate with low viraemia, delayed onset of AIDS and, possibly, cytotoxic

79 The median time of BK viraemia development post-transplant was 279.5 days comp

80 well as identify risk factors for BKN and BK viraemia development.

81 nst all four dengue virus serotypes, and the viraemia due to each of the four vaccine components afte

82 es are not adequate to reduce high fever and viraemia duration.

83 time to viral rebound correlated with total viraemia during acute infection and with proviral DNA at

84 We investigated the occurrence of detectable viraemia during ART below this threshold and its effect

85 viraemia and improved the time-to-event for viraemia episodes compared with placebo.

86 logical suppression, patients with low-level viraemia, even at 51-199 copies per mL, had increased od

87 a single treatment rapidly suppressed plasma viraemia for 3-5 weeks in some long-term chronically SHI

88 er half-life of antibodies led to control of viraemia for an average of 60 days after cessation of th

89 er vector competence and shorter duration of viraemia for SBV compared with BTV.

90 c variability in the within-host dynamics of viraemias for a population of patients using the method

91 es maintained complete suppression of plasma viraemia (for up to 43 weeks) after analytical treatment

92 Our primary endpoint was any viraemia greater than 50 copies per mL.

93 dan virus disease associated with high-titre viraemia (>1 x 10(8) TCID(50) per mL), high viral organ

94 Patients with low-level viraemia had increased risk of virological failure (adju

95 Patients with low-level viraemia had increased risk of virological non-suppressi

96 Prevalence of viraemia had the strongest correlation with HIV incidenc

97 in a dengue patient and the duration of this viraemia has a profound effect on whether or not a mosqu

98 Durable post-intervention control (PIC) of viraemia has been achieved in a subset of people followi

99 h recent immunosuppression and prolonged HIV viraemia have important independent roles in the develop

100 While all sham-vaccinated animals developed viraemia, high tissue viral loads and CCHF-induced disea

101 the community programme, shorter duration of viraemia, higher CD4 count and transfers into programme

102 workplace patients had a longer duration of viraemia, higher VL, lower CD4 count, and higher reporte

103 e failure of ART with a lenient threshold of viraemia (HIV RNA viral load >/=1000 copies per mL).

104 abnormalities following exposure to maternal viraemia, immune dysfunction, and co-infections during p

105 ximal leakage occurs several days after peak viraemia implicating immunological pathways.

106 termine whether treatment of cytomegalovirus viraemia improves outcomes in advanced HIV disease.

107 aphical locations with high-level detectable viraemia in east Africa.

108 ntibodies can prevent infection and suppress viraemia in humanized mice and nonhuman primates, but th

109 heir ability to block infection and suppress viraemia in macaques infected with the R5 tropic simian-

110 itin specifically neutralize ZIKV and reduce viraemia in mice.

111 Judicious monitoring of BK viraemia in paediatric transplant recipients, coupled wi

112 inally, rimantadine effectively blocked ZIKV viraemia in preclinical models, supporting that M consti

113 lude: age-specific prevalence studies of HCV viraemia in priority countries; further validation of no

114 viral load-the approximately stable value of viraemia in the first years of chronic infection-is a st

115 accine (TransVax) for clinically significant viraemia in the HSCT setting.

116 ompared the incidence and persistence of HCV viraemia in these two groups over four consecutive 6-mon

117 pecific focus on the effect of ART and HIV-1 viraemia in those co-infected with HIV-1.

118 We investigated the frequency of TTV viraemia in UK blood donors, and the extent to which TTV

119 o spontaneously maintain undetectable plasma viraemia is a major objective of HIV-1 cure research, bu

120 Cytomegalovirus viraemia is associated with an increased risk of overall

121 can be prevented by giving ganciclovir when viraemia is detected in allograft recipients.

122 TTV viraemia is frequent in the blood-donor population, and

123 Strategies for management of low-level viraemia need to be incorporated into WHO guidelines to

124 a rare, polyclonal form of non-suppressible viraemia (NSV).

125 e we show that sudden breakthrough of plasma viraemia occurred after prolonged immune containment in

126 ERPRETATION: In this large cohort, low-level viraemia occurred frequently and increased the risk of v

127 Low-level viraemia occurred in 16 013 (23%) of 69 454 patients, wi

128 A low-level, transient, dose-dependent viraemia occurred in concert with early reactogenicity.

129 gical failure--which we defined as confirmed viraemia of more than 1000 copies per mL--in the switch

130 We found viraemia of more than 60 copies per ml in all macaques (

131 mpromised local viral retention, exacerbated viraemia of the host, and impaired local B-cell activati

132 ed with a lower median viral load after peak viraemia off ART.

133 Participants had undetectable viraemia on ART and CD4 counts >350 cells/uL.

134 Among people with viraemia on dolutegravir-based ART, INSTI DRMs and dolut

135 cabotegravir and rilpivirine than those with viraemia on dolutegravir-based ART.

136 bitor (INSTI) resistance in individuals with viraemia on LAI cabotegravir and rilpivirine than those

137 ptive therapy for documented cytomegalovirus viraemia, onset of cytomegalovirus end-organ disease, or

138 oad thresholds or a definition for low-level viraemia or did not provide quantitative viral load info

139 mice infected with HCV results in measurable viraemia over several weeks.

140 nset delayed, reflecting significantly lower viraemia (p<0.0001) and blood monocyte-activation patter

141 titres correlated inversely with duration of viraemia (p=0.0022).

142 ts with seropositive donors, the duration of viraemia (p=0.0480) and number of days of ganciclovir tr

143 opulation-level prevalence of detectable HIV viraemia (PDV) has been proposed as a metric for monitor

144 CD4 antigen (CD4(+)) and very low levels of viraemia persisted for over 2 years.

145 ation in vitro are less likely to experience viraemia post-transplant.

146 in the donor organ can reduce the chance of viraemia post-transplant.

147 n serve as the last reporter of the residual viraemia, postulating that the absence of T-cell immune

148 To better understand low-level viraemia prevalence and outcomes, we analysed retrospect

149 oss-reactive antibodies prolonged YF vaccine viraemia, provoked greater pro-inflammatory responses, a

150 d transfer inhibitors for the same low-level viraemia range.

151 n of HIV from individuals with low-level HIV viraemia receiving antiretroviral therapy (ART) has impo

152 -1-infected individuals by 0.8-2.5 log10 and viraemia remained significantly reduced for 28 days.

153 Viraemia remained undetectable for 56-177 days, dependin

154 We have investigated whether cytomegalovirus viraemia remains a significant risk factor for progressi

155 ent control' (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped.

156 en in this context, and that cytomegalovirus viraemia represents a potentially modifiable risk factor

157 he occurrence rate of clinically significant viraemia resulting in initiation of cytomegalovirus-spec

158 Delaying start of treatment until peak viraemia results in a rapid and significant reduction in

159 Many children with detectable low-level viraemia spontaneously resuppressed, highlighting the im

160 BTV infection of ruminants results in a high viraemia, suggesting that repeated sharing of needles be

161 on, and tight correlation of PET signal with viraemia suggests target-cell activation determines stea

162 pants with high-level cytomegalovirus plasma viraemia than in participants without cytomegalovirus pl

163 fections are characterized by early peaks of viraemia that decline as strong cellular immune response

164 characterized by: occasional blips of plasma viraemia that ultimately waned; predominantly undetectab

165 on dynamics showed that the duration of HCMV viraemia, the peak viral load, and the growth rate of HC

166 serodiscordant couples at various levels of viraemia, the science behind undetectable=untransmittabl

167 gh the Zika virus (ZIKV) rapidly establishes viraemia, the target cells and immune responses, particu

168 in a rapid and precipitous decline of plasma viraemia to undetectable levels in rhesus monkeys chroni

169 tus during symptomatic and asymptomatic EEHV viraemia, to potentially support the use of anti-inflamm

170 We tested for viraemia, undertook analyses for haematology and serum b

171 We analysed risk for low-level viraemia, virological non-suppression, and virological f

172 This sudden increase in viraemia was associated with a decline in half of the CD

173 Conversely, EBV plasma viraemia was associated with higher CD4 cell counts and

174 Low-level viraemia was associated with increased hazards of virolo

175 Cytomegalovirus plasma viraemia was associated with lower CD4 cell counts, less

176 Development of BK viraemia was associated with negative recipient serology

177 Viraemia was confirmed by PCR.

178 load in the year preceding elicitation, and viraemia was defined as a viral load of 200 copies per m

179 Low-level viraemia was defined as the occurrence of at least one v

180 TTV viraemia was detected in 19 (1.9%) of 1000 non-remunerat

181 g resting CD4(+) T cells of patients in whom viraemia was fully suppressed by antiretroviral therapy,

182 Enterovirus D68 viraemia was identified in a child experiencing acute ne

183 HIV-positive mothers who cleared the virus, viraemia was intermittent.

184 Prevalence of viraemia was more strongly correlated with HIV incidence

185 Cytomegalovirus plasma viraemia was present in 395 (49%) of 804 participants an

186 395 (49%) of 804 participants and EBV plasma viraemia was present in 585 (73%) participants.

187 r 402 668 patients during 2016-21, low-level viraemia was present in 64 480 (16.0%) individuals and v

188 Maternal inflammation and cytomegalovirus viraemia were independently associated with infant death

189 ection, experienced sustained rebound plasma viraemia when treatment was interrupted.

190 ssociated with very low levels of persistent viraemia, which leads to the establishment of T-cell imm

191 t outcomes for children and adolescents with viraemia while taking ART.

192 s in epitopes associated with suppression of viraemia will accumulate as the epidemic progresses, and

193 Panobinostat induced plasma viraemia with an odds ratio of 10.5 (95% CI 2.2-50.3; p

194 setting, few data are available correlating viraemia with clinical endpoints.

195 Both exhibited rapid, high, acute viraemia with early neuroinvasion (3 days) in peripheral

196 hown to reduce the magnitude and duration of viraemia with re-challenge.

197 uick and accurate approach for assessing HIV viraemia, with excellent concordance with validated labo

198 1b, 2a or 3 resulted in a 2-log reduction in viraemia, without evidence of drug resistance.

199 rcentage point in a community, prevalence of viraemia would need to be reduced by 4.34%, and ART use

200 NA and are rapidly eliminated at the peak of viraemia, yet the mechanism by which HIV-1 induces helpe